Filter Results:
(1,253)
Show Results For
- All HBS Web
(1,253)
- People (5)
- News (177)
- Research (922)
- Events (6)
- Multimedia (12)
- Faculty Publications (754)
Show Results For
- All HBS Web
(1,253)
- People (5)
- News (177)
- Research (922)
- Events (6)
- Multimedia (12)
- Faculty Publications (754)
- January 2007 (Revised January 2007)
- Background Note
Note on the U.S. Food and Drug Administration
By: Robert F. Higgins, Richard G. Hamermesh and Virginia Fuller
Describes the U.S. FDA with particular emphasis on its role in the development of new drugs, biologic products, and medical devices today. Provides context for the drug approval process by describing the FDA's history and organizational structure. View Details
Keywords: Health; Governance Compliance; Policy; Product Development; Government and Politics; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; United States
Higgins, Robert F., Richard G. Hamermesh, and Virginia Fuller. "Note on the U.S. Food and Drug Administration." Harvard Business School Background Note 807-050, January 2007. (Revised January 2007.)
- 04 Apr 2022
- Research & Ideas
Tech Hubs: How Software Brought Talent and Prosperity to New Cities
period. Software is penetrating other industries, Kerr notes. Take vaccines. Pharmaceutical companies’ speedy development of mRNA-based vaccines for COVID-19 required software, he notes. “Their capacity to bring a substantial software, AI... View Details
Keywords: by Rachel Layne
- 01 Aug 2001
- News
Cleveland Global Alumni Conference a Sold-Out Success
& Co., kicked off the first plenary session with a quick overview of factors contributing to the U.S. pharmaceutical industry's success in competing in the global market. Among other ad- vantages, Gilmartin cited the U.S. government's... View Details
- September 2003 (Revised February 2007)
- Case
PolyMedica Corporation (A)
By: David F. Hawkins and Jacob Cohen
The Securities and Exchange Commission and investors question PolyMedica Corp.'s practice of capitalizing rather than expensing of direct-response advertising. View Details
Keywords: Activity Based Costing and Management; Business Earnings; Advertising; Private Sector; Budgets and Budgeting; Cost Management; Capital Markets; Marketing; Private Equity; Pharmaceutical Industry; Pharmaceutical Industry
Hawkins, David F., and Jacob Cohen. "PolyMedica Corporation (A)." Harvard Business School Case 104-023, September 2003. (Revised February 2007.)
- 06 Jun 2017
- First Look
First Look at New Research and Ideas: June 6, 2017
regulatory pathway, the biosimilars pathway, on the strategy of a major pharmaceutical firm that finds its largest product (60% of revenue) at risk. The case reviews the rationale for the pathway, the emerging biosimilars market entrants,... View Details
Keywords: Sean Silverthorne
- 16 Dec 2020
- Blog Post
Faculty Books Published in 2020
growth and the transformation of knowledge into new products and processes. A third reviews different innovation policies and their performance in the pharmaceutical sector. Next is a chapter on the effects of competition policy on... View Details
Keywords: All Industries
- 26 Jan 2009
- Research & Ideas
Where is Home for the Global Firm?
you share these ideas? A: Of course, once you write something like this, you come to see many things through these lenses. As reported in the Financial Times in October, several UK firms including Shire Pharmaceuticals and WPP Group have... View Details
Keywords: by Martha Lagace
- 01 Feb 2000
- News
Executives Convene to Discuss Consumer-Driven Health Care
alumni event attracted more than sixty HBS graduates representing biotechnology, e-commerce, managed care, and pharmaceutical companies. The program featured briefings from HBS faculty members interested in issues related to health-care... View Details
- 23 Oct 2019
- News
After the Storm
class. When I started at Johnson & Johnson right after business school, I remember being the only African American female pharmaceutical sales rep in the mid-Atlantic region at that time. It’s a sad reality, but that is also why I get so... View Details
- 11 Nov 2015
- Working Paper Summaries
Public R&D Investments and Private-sector Patenting: Evidence from NIH Funding Rules
- September 2003 (Revised January 2004)
- Case
PolyMedica Corporation (B)
By: David F. Hawkins and Jacob Cohen
Supplements the (A) case. View Details
Hawkins, David F., and Jacob Cohen. "PolyMedica Corporation (B)." Harvard Business School Case 104-031, September 2003. (Revised January 2004.)
- 03 Mar 2015
- First Look
First Look: March 3
model, the company would sell sequencers at a higher price to those entities that already purchased sequencers, primarily major research labs and pharmaceutical firms, but position its machine as a faster alternative to existing... View Details
Keywords: Sean Silverthorne
- 20 Feb 2018
- First Look
First Look at New Research and Ideas, February 20, 2018
new fund. Purchase this case: https://cb.hbsp.harvard.edu/cbmp/product/317036-PDF-ENG Harvard Business School Case 118-052 Charity or Bribery? Filip Kowalski, a senior manager at the pharmaceutical company Healthgen, leads sales for the... View Details
Keywords: Sean Silverthorne
- 03 Jan 2017
- First Look
January 3, 2017
silos within numerous academic medical centers, pharmaceutical companies, and some disease-based foundations. For new precision therapies to be developed, these data sets need to be shared broadly. Patients can help lead this effort by... View Details
Keywords: Carmen Nobel
- 18 Aug 2011
- Lessons from the Classroom
Business Plan Contest: 15 Years of Building Better Entrepreneurs
asking, is this the right business model? But there are no answers. The market and technology are constantly changing," Riesenfeld remarks. Important Sounding Board The biotech industry presents similar challenges in a space littered with failed companies. When... View Details
- 01 Jun 2011
- News
The Best-Laid Plans
failed companies. When Potentia Pharmaceuticals won the contest in 2001 with Alec Machiels (MBA 2001) at the helm, its plan hinged on a mechanism created by a team of Harvard and MIT scientists that used atomic force microscopy in drug... View Details
- 20 Jul 2022
- News
Wired to be Inspired
understand, first of all, don't get confused by purpose statements. Theranos had one. Purdue Pharmaceutical had one. Facebook pulled one out in 2016 when they were in trouble. And you read those statements and you’re like, you gotta be... View Details
- 16 Jun 2015
- First Look
First Look: June 16, 2015
particularly in the vaccine space, had begun to attract the attention of much larger pharmaceutical companies. While there was much appeal to working with these companies, these relationships could also challenge Crucell's independence.... View Details
Keywords: Sean Silverthorne
- 18 Jun 2001
- Research & Ideas
When In-House Research Isn’t Enough
protection in the pharmaceutical and life sciences arena, said Chesbrough. But if you're in IT, forget about it. Can you sustain the pace of innovation necessary for success? The answers to the previous questions have an impact on this... View Details
Keywords: by Jim Aisner
- 23 Aug 2018
- News
Healthcare Alumni Keep Learning Through Virtual Programming
pharmaceutical CEO’s perspective on what’s next in Alzheimer’s research; and a panel discussion on the digital transformation of health care. “While many other organizations might claim to offer similar topics, the VRT series is designed... View Details